Trial Profile
A Randomized, Double-blind, Placebo-controlled, Two-period Crossover Study to Assess the Effect of Inhaled QVA149 on Global and Regional Lung Function and Gas Exchange in Patients With Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals Corporation
- 18 Jun 2018 Status changed from recruiting to completed.
- 12 Sep 2017 Planned End Date changed from 1 Sep 2017 to 15 Nov 2017.
- 12 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 15 Nov 2017.